<%@ Language=VBScript %> <%Call Header("Home")%>

Copernicus Therapeutics, Inc. is a privately-held company developing products for human gene therapy and vaccination. Copernicus was established in 1997 based on technologies discovered at Case Western Reserve University that provide the foundation for the use of DNA as drugs. Copernicus is not involved in gene discovery or the linkage of genetic defects to disease. Copernicus' business focuses on using its technologies to make and sell gene therapy products to treat, cure or prevent human diseases - products that work. Copernicus Therapeutics, Inc. presented data at the American Society of Gene Therapy meeting showing that their compacted DNA formulation can effectively transfect non-dividing human cells, solving the problem of restricted access of plasmid DNA to the nucleus. ..read more Copernicus has developed three technology platforms that provide unique opportunities to develop novel therapeutics. These platforms have separate therapeutic applications but, when combined, can result in synergistic advantages. Copernicus' technologies present opportunities for products in many important markets. The Company's delivery technologies solve many of the problems that have hindered gene therapy, with a market projected to be worth $12 billion by 2007. ..read more Copernicus has exclusive, world-wide licenses to twelve U.S. patents issued to Case Western Reserve University, three U.S. patents issued to Copernicus and four pending U.S. patent applications that provide strong support for the commercialization of its technologies. Over 30 non-US patents extend protection throughout world markets. ..read more

<%Call Footer()%>